SIRFLOX Key Findings


SIR-Spheres® Y-90 resin microspheres + mFOLFOX6 (+ bev*) in mCRC

  • No statistically significant improvement of PFS at any site.1
  • Risk of first progression in the liver as per competing risk analysis significantly lower for patients receiving SIR-Spheres Y-90 resin microspheres. The improvement was 7.9 month with an HR of 0.69 corresponding to a 31% reduction in risk of progression in the liver at any point in time.1
  • Statistically significant increase of hepatic Depth of Response (DpR) by 20% in patients with >12% tumour burden and >100 day increase in Time to Nadir compared to chemotherapy alone.2
  • Three-fold increase in complete response rate in the liver.1
  • Statistically significant increase in hepatic response rate.1
  • A retrospective analysis showed a statistically significant increase in number of patients rendered technically resectable following the addition of SIR-Spheres Y-90 resin microspheres to chemo.3

SIRFLOX was the first large, randomised, controlled, open-label, multicentre international study to examine the use of chemo-radiotherapy in the first-line treatment of colorectal liver metastases.

The study evaluated the efficacy and safety of adding SIR-Spheres Y-90 resin microspheres to a current first-line systemic chemotherapy in patients with unresectable colorectal liver metastases.

Summary of SIRFLOX study data

1. van Hazel GA et al. J Clin Oncol 2016; 34:1723–31.
2. Heinemann V et al. ESMO WCGIC, Annals of Oncology 2016; 27 (Suppl 2): Abs. O-014.
3. Garlipp B et al. E-AHPBA 2017; Abs. FP 15.08



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage